Home › Research › Drug development
Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia
Decourt B, Noorda K, Noorda K, Shi J, Sabbagh MN.. Journal of experimental pharmacology, 2022-10-30
Topic: Amyloid, tau and blood-test diagnosis
Alzheimer disease (AD) is the most common neurodegenerative disease and typically affects patients older than age 65. Around this age, the number of neurons begins to gradually decrease in healthy brains, but brains of patients with AD show a marked increase in neuron death, often resulting in a significant loss of cognitive abilities. Cognitive skills affected include information retention, recognition capabilities, and language skills.
Key findings
- Around this age, the number of neurons begins to gradually decrease in healthy brains, but brains of patients with AD show a marked increase in neuron death, often resulting in a significant loss of cognitive abilities.
- Cognitive skills affected include information retention, recognition capabilities, and language skills.
- At present, AD can be definitively diagnosed only through postmortem brain biopsies via the detection of extracellular amyloid beta (Aβ) plaques and intracellular hyperphosphorylated tau neurofibrillary tangles.
- Because the levels of both Aβ plaques and tau tangles are increased, these 2 proteins are thought to be related to disease progression.
Why it matters
This review discusses advanced drug trials focused on reducing brain beta-amyloid to prevent and treat dementia, and notes that at present Alzheimer's disease can be definitively diagnosed only through postmortem brain biopsies. It describes the state of drug development rather than reporting a proven cure or prevention.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of experimental pharmacology) |
| Journal's citation record | 0 / 4 | Journal of Experimental Pharmacology: journal h-index 38 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 32 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.3 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 3 / 6 | Cited 3.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 21 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Marwan Noel Sabbagh: h-index 65 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Cleveland Clinic: institution h-index 1,139 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 36339394) |
| Free to read | 2 / 2 | Free to read |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.2147/jep.s265626
- PubMed: 36339394
- Original source →
- Free full text: Journal of Experimental Pharmacology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Decourt, B., Noorda, K., Shi, J., & Sabbagh, M. N. (2022). Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia. Journal of experimental pharmacology. https://doi.org/10.2147/jep.s265626
Vancouver
Decourt B, Noorda K, Shi J, Sabbagh MN. Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia. Journal of experimental pharmacology. 2022. doi:10.2147/jep.s265626. PMID: 36339394.
BibTeX
@article{decourt2022-36339394,
author = {Decourt, B. and Noorda, K. and Shi, J. and Sabbagh, M. N.},
title = {{Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia}},
journal = {Journal of experimental pharmacology},
year = {2022},
doi = {10.2147/jep.s265626},
pmid = {36339394},
url = {https://doi.org/10.2147/jep.s265626}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.